The latest price target for Xenetic Biosciences (NASDAQ:XBIO) was reported by HC Wainwright & Co. on December 5, 2024. The analyst firm set a price target for $0.00 expecting XBIO to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Xenetic Biosciences (NASDAQ:XBIO) was provided by HC Wainwright & Co., and Xenetic Biosciences reiterated their neutral rating.

There is no last upgrade for Xenetic Biosciences

The last downgrade for Xenetic Biosciences Inc happened on May 16, 2023 when HC Wainwright & Co. changed their price target from N/A to N/A for Xenetic Biosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xenetic Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xenetic Biosciences was filed on December 5, 2024 so you should expect the next rating to be made available sometime around December 5, 2025.

While ratings are subjective and will change, the latest Xenetic Biosciences (XBIO) rating was a reiterated with a price target of $0.00 to $0.00. The current price Xenetic Biosciences (XBIO) is trading at is $4.29, which is out of the analyst’s predicted range.